The DOI matches its Crossref record.
Vasodepressor Actions of Angiotensin-(1–7) Unmasked During Combined Treatment With Lisinopril and Losartan
Open accessAbstract
Abstract—Blockade of angiotensin II (Ang II) function during 8 days of oral therapy with lisinopril (20 mg/kg) and losartan (10 mg/kg) normalized the arterial pressure (112±3/70±3 mm Hg) and raised the plasma concentrations of the vasodilator peptide angiotensin-(1–7) [Ang-(1–7)] of 21 male spontaneously hypertensive rats (SHR). Treated animals were then given a 15-minute infusion of either mouse immunoglobulin G 1 or a specific monoclonal Ang-(1–7) antibody while their blood pressure and heart rate were recorded continuously in the awake state. The concentrations of Ang II and Ang-(1–7) in arterial blood were determined by radioimmunoassay. Infusion of the Ang-(1–7) antibody caused significant elevations in mean arterial pressure that were sustained for the duration of the infusion and were accompanied by transient bradycardia. Although the hemodynamic effects produced by infusion of the Ang-(1–7) antibody had no effect on plasma levels of Ang II, they caused a twofold rise in the plasma concentrations of Ang-(1–7). A pressor response of similar magnitude and characteristics was obtained in a separate group of SHR treated with the combination of lisinopril and losartan for 8 days during an infusion of [Sar 1-Thr 8]Ang II. The pressor response induced by the administration of this competitive, non–subtype-selective Ang II receptor blocker was not modified by pretreatment of the rats with an angiotensin type-2 (AT 2) receptor blocker (PD123319). Plasma concentrations of Ang II and Ang-(1–7) were not changed by the administration of [Sar 1-Thr 8]Ang II either in the absence or in the presence of PD123319 pretreatment. These results are the first to indicate an important contribution of Ang-(1–7) in mediating the vasodilator effects caused by combined inhibition of angiotensin-converting enzyme and AT 1 receptors. The comparable results obtained by administration of [Sar 1-Thr 8]Ang II suggest that the vasodepressor effects of Ang-(1–7) during the combined treatment is modulated by a non-AT 1/AT 2 angiotensin subtype receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ferrario, C. M., Jessup, J., Chappell, M. C., Averill, D. B., Brosnihan, K. B., Tallant, E. A., Diz, D. I., & Gallagher, P. E. (2005) · Circulation · doi:10.1161/circulationaha.104.510461 · Cited by 1,565
Self-citationACE2, angiotensin‐(1‐7) and Mas receptor axis in inflammation and fibrosis
Simões e Silva, A., Silveira, K., Ferreira, A., & Teixeira, M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12159 · Cited by 542
Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets
Jiang, F., Yang, J., Zhang, Y., Dong, M., Wang, S., Zhang, Q., Liu, F. F., Zhang, K., & Zhang, C. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.59 · Cited by 426
Ferrario, C. M., Trask, A. J., & Jessup, J. A. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00618.2005 · Cited by 385
Self-citationSantos, R. A. S., Campagnole-Santos, M. J., & Andrade, S. P. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00138-5 · Cited by 380
Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren
Stanton, A., Jensen, C., Nussberger, J., & O'Brien, E. (2003) · Hypertension · doi:10.1161/01.hyp.0000101688.17370.87 · Cited by 341
Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the mas receptor
Tallant, E. A., Ferrario, C. M., & Gallagher, P. E. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00941.2004 · Cited by 318
Self-citationZisman, L. S., Keller, R. S., Weaver, B., Lin, Q., Speth, R., Bristow, M. R., & Canver, C. C. (2003) · Circulation · doi:10.1161/01.cir.0000094734.67990.99 · Cited by 308
Karnik, S. S., Unal, H., Kemp, J. R., Tirupula, K. C., Eguchi, S., Vanderheyden, P. M. L., & Thomas, W. G. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010454 · Cited by 302
Metabolism of Angiotensin-(1–7) by Angiotensin-Converting Enzyme
Chappell, M. C., Pirro, N. T., Sykes, A., & Ferrario, C. M. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.362 · Cited by 289
Self-citationAngiotensin-Converting Enzyme II in the Heart and the Kidney
Danilczyk, U., & Penninger, J. M. (2006) · Circulation Research · doi:10.1161/01.res.0000205761.22353.5f · Cited by 269
Ferrario, C. M., Jessup, J., Gallagher, P. E., Averill, D. B., Brosnihan, K. B., Ann Tallant, E., Smith, R. D., & Chappell, M. C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00675.x · Cited by 259
Self-citationRenin inhibition with aliskiren: where are we now, and where are we going?
Azizi, M., Webb, R., Nussberger, J., & Hollenberg, N. K. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000202812.72341.99 · Cited by 253
The depressor axis of the renin–angiotensin system and brain disorders: a translational approach
Gironacci, M. M., Vicario, A., Cerezo, G., & Silva, M. G. (2018) · Clinical Science · doi:10.1042/cs20180189 · Cited by 60
Metadata
- Authors
- Iyer, S. N., Chappell, M. C., Averill, D. B., Diz, D. I., & Ferrario, C. M.
- Venue
- Hypertension
- Published
- 1998-02
- Volume
- 31
- Issue
- 2
- Pages
- 699-705
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2160071918
- Cited by
- 227
- References
- 0
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.